Literature DB >> 21315698

Formaldehyde-inactivated human enterovirus 71 vaccine is compatible for co-immunization with a commercial pentavalent vaccine.

Chun-Wei Chen1, Yi-Ping Lee, Ya-Fang Wang, Chun-Keung Yu.   

Abstract

In this study we tested the effectiveness of a formaldehyde-inactivated EV71 vaccine and its compatibility for co-immunization with a pentavalent vaccine that contained inactivated poliovirus (PV) vaccine. The inactivated EV71 vaccine (C2 genogroup) elicited an antibody response which broadly neutralized homologous and heterologous genogroups, including B4, C4, and B5. Pups from vaccinated dams were resistant to the EV71 challenge and had a high survival rate and a low tissue viral burden when compared to those from non-vaccinated counterparts. Co-immunization with pentavalent and inactivated EV71 vaccines elicited antibodies against the major components of the pentavalent vaccine including the PV, Bordetella pertussis, Haemophilus influenzae type b, diphtheria toxoid, and tetanus toxoid at the same levels as in mice immunized with pentavalent vaccine alone. Likewise, EV71 neutralizing antibody titers were comparable between EV71-vaccinated mice and mice co-immunized with the two vaccines. These results indicate that formaldehyde-inactivated whole virus EV71 vaccine is feasible for designing multivalent vaccines.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21315698     DOI: 10.1016/j.vaccine.2011.01.094

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  Cell-culture derived fowl adenovirus serotype 4 inactivated vaccine provides complete protection for virus infection on SPF chickens.

Authors:  Dongying Du; Pantao Zhang; Xiangdong Li; Hui Tian; Yi Cheng; Dongbei Sheng; Xueying Han; Yihong Shan; Xuefeng Li; Yue Yuan; Haiyang Zhang; Jingjing Xue; Wujie Liu; Kegong Tian
Journal:  Virusdisease       Date:  2017-05-10

Review 2.  Is a multivalent hand, foot, and mouth disease vaccine feasible?

Authors:  Michel Klein; Pele Chong
Journal:  Hum Vaccin Immunother       Date:  2015-05-26       Impact factor: 3.452

3.  The immunogenicity and protection effect of the BPL-inactivated CA16 vaccine in different animal systems.

Authors:  Wen Qi An; Zhi Guo Su; Ruo Wen Pan; Bao Ping Yang; Yong Chao Zhang; Liang Shi; Qing Li
Journal:  Hum Vaccin Immunother       Date:  2014-01-08       Impact factor: 3.452

Review 4.  Therapeutic and prevention strategies against human enterovirus 71 infection.

Authors:  Chee Choy Kok
Journal:  World J Virol       Date:  2015-05-12

Review 5.  Progress on the research and development of human enterovirus 71 (EV71) vaccines.

Authors:  Zhenglun Liang; Qunying Mao; Fan Gao; Junzhi Wang
Journal:  Front Med       Date:  2012-12-17       Impact factor: 4.592

6.  A neonatal mouse model of coxsackievirus A16 for vaccine evaluation.

Authors:  Qunying Mao; Yiping Wang; Rong Gao; Jie Shao; Xin Yao; Shuhui Lang; Chao Wang; Panyong Mao; Zhenglun Liang; Junzhi Wang
Journal:  J Virol       Date:  2012-09-05       Impact factor: 5.103

7.  Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human enterovirus 71 strains in mice.

Authors:  Tao Meng; Annasaheb B Kolpe; Tanja K Kiener; Vincent T K Chow; Jimmy Kwang
Journal:  PLoS One       Date:  2011-07-01       Impact factor: 3.240

8.  Optimization and Characterization of Candidate Strain for Coxsackievirus A16 Inactivated Vaccine.

Authors:  Jingliang Li; Guanchen Liu; Xin Liu; Jiaxin Yang; Junliang Chang; Wenyan Zhang; Xiao-Fang Yu
Journal:  Viruses       Date:  2015-07-17       Impact factor: 5.048

Review 9.  Strategies to develop antivirals against enterovirus 71.

Authors:  Rei-Lin Kuo; Shin-Ru Shih
Journal:  Virol J       Date:  2013-01-22       Impact factor: 4.099

Review 10.  Recent Progress towards Novel EV71 Anti-Therapeutics and Vaccines.

Authors:  Qingyong Ng; Fang He; Jimmy Kwang
Journal:  Viruses       Date:  2015-12-08       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.